SCHEMBL5058266

SCHEMBL5058266

NC(=O)C1[CH]CN1c1ccncc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
MAPT P10636 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CHKA P35790 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
CYP2C9 P11712 3/20 0.33
CYP3A4 P08684 3/20 0.33
TSHR P16473 1/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
USP2 O75604 1/20 0.33
BCHE P06276 1/20 0.32
CYP2C19 P33261 2/20 0.32
HSD17B10 Q99714 1/20 0.32
NPC1 O15118 1/20 0.32
CHRNB2 P17787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15991903 0.70 CHKA (0.36) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL15992145 0.70 CHKA (0.36) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL6513376 0.69 PIM1 (0.43) CHKAF10
SCHEMBL5053496 0.68 CHKA (0.44) CHKAITGB3ITGA2BCYP2C9CYP3A4
SCHEMBL11907565 0.67 CHKA (0.36) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL1674952 0.67 MAPT (0.33) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL4700677 0.66 SYK (0.39) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL2780304 0.66 CYP3A4 (0.54) MAPTNPSR1CHKAITGB3ITGA2B
SCHEMBL4723259 0.65 LSS (0.46) ITGB3ITGA2BCYP3A4LMNAF10
SCHEMBL6703929 0.61 SMN1; SMN2 (0.50) MAPTNPSR1CHKAITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569927-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP claimed
US-20040171604-A1 Imidazole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-02 US claimed
WO-2004050636-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 WO claimed
US-7358268-B2 Imidazole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-15 US disclosed
EP-1569927-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP disclosed
US-20040171604-A1 Imidazole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-09-02 US disclosed
WO-2004050636-A2 IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171604-A1 Imidazole derivatives as factor Xa inhibitors TFPI, F11, TFPI2 MAOA 76/4885MAOB 58/4885MAPT 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.